Trial | NCT00936260  Report issue

Official Title

Drug Holidays in the Treatment With Alendronate in Postmenopausal Women With Osteoporosis

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    228
The purpose of this study is to determine the duration of the treatment with alendronate in postmenopausal women with osteoporosis.
The duration of the treatment with alendronate is not well established. The investigators recruited 228 women with postmenopausal osteoporosis. They all received alendronate during the first 3 years of monitoring and were later on randomized to whether different regimens of intermittent treatment or to carry on 3 years more.
Study Started
Jan 31
1998
Primary Completion
Dec 31
2004
Study Completion
Dec 31
2004
Last Update
Jul 10
2009
Estimate

Drug alendronate

several duration of treatment

  • Other names: fosamax

alendronate 6 years Experimental

alendronate 5 years Experimental

No treatment during year 6th

alendronate 5 years, not continued Experimental

No treatment during year 5th

alendronate 4 years Experimental

No treatment during year 5th and 6th

alendronate 5 years, uncontinued Experimental

No treatment during year 4th

alendronate 4 years, not continued Experimental

No treatment during year 4th and 6th

alendronate 4 years, uncontinued Experimental

No treatment during year 4th and 5th

Alendronato 3 years Experimental

No treatment during the last 3 years

Criteria 

Inclusion Criteria:

postmenopausal osteoporosis under densitometric criteria of the World Health Organization

Exclusion Criteria:

secondary osteoporosis
alteration in analytic parameters (total proteins, calcium, phosphorus, vitamin D, parathyroid hormone, thyroid hormone, transaminase, creatinine)
No Results Posted